Prevail Therapeutics Inc

Prevail Therapeutics — Investor Presentation (March 2020)

30 slides from Prevail Therapeutics's investor presentation, Mar 3, 2020

  1. Slide 1: Corporate Presentation March 2020

    Corporate Presentation MARCH 2020 Exhibit 99.3

  2. Slide 2: Forward-looking statements and third-party data

    Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Prevail Therapeutics Inc.’s (“Prevail”) own internal estimates and research. While Prev

  3. Slide 3: Prevail Therapeutics overview

    Prevail Therapeutics overview Enrollment ongoing in Phase 1/2 PROPEL trial for Parkinson’s with GBA mutation (PD-GBA); PD-GBA affects >90K Americans Potential for rapid proof-of-concept for PR001 in neuronopathic Gaucher disease; IND active and planned to enter the clinic in 2020 Large Market & Near

  4. Slide 4: Rapid execution in developing gene therapies for patients with urgent unmet needs

    2017 2018 2019 2020 Rapid execution in developing gene therapies for patients with urgent unmet needs OCTOBER 2017: Lab space secured in NYC AUGUST 2017: Seed financing and REGENXBIO license MAY 2018: REGENXBIO second agreement MARCH 2018: $75M Series A MAY 2019: PR001 PD-GBA IND active MARCH 2019:

  5. Slide 5: Management and Board of Directors

    Management and Board of Directors Experienced Management Team Board of Directors Asa Abeliovich, MD, PhD CEO and Founder Carl Gordon, PhD, CFA OrbiMed Francois Nader, MD Non-Executive Chairman Ran Nussbaum Pontifax Peter Thompson, MD OrbiMed Asa Abeliovich, MD, PhD CEO and Founder Yong Dai, PhD Chie

  6. Slide 6: Pipeline of disease-modifying AAV9 gene therapies for neurodegenerative diseases

    Pipeline of disease-modifying AAV9 gene therapies for neurodegenerative diseases ODD and RPDD granted by FDA for PR001 for the treatment of GD and nGD, respectively ODD granted by FDA for PR006 for the treatment of FTD Prevail owns worldwide commercial rights to all product candidates in the pipelin

  7. Slide 7: Precision genetic medicine approach to neurodegenerative diseases

    Precision genetic medicine approach to neurodegenerative diseases Mutated Gene Disease DYSFUNCTIONAL LYSOSOME PATHWAY INFLAMMATION CELL TOXICITY PROTEIN AGGREGATION SUBSTRATE ACCUMULATION Human genetic studies have identified genes that cause or increase risk of neurodegenerative diseases Many of th

  8. Slide 8: AAV9 is well-suited to deliver functional genes or gene knockdown to the CNS

    AAV9 is well-suited to deliver functional genes or gene knockdown to the CNS Gene cargo AAV9 delivery vector CNS administration Viral transduction and transgene expression AAV9-based therapy has shown transformative efficacy and safety and is now approved for SMA The effectiveness of AAV9-based ther

  9. Slide 9: PR001 overview

    PR001 overview PR001 Route of Administration Lead Indications Progress and Status AAV9 viral vector delivering the GBA1 gene, which encodes glucocerebrosidase (GCase) Single intra-cisterna magna (ICM) injection Parkinson’s disease with at least one GBA1 mutation (PD-GBA) Earlier disease onset, more

  10. Slide 10: Parkinson's disease progression and unmet need

    Early disease manifests with non-motor and subtle motor symptoms With disease progression motor symptoms worsen and cognitive & behavioral symptoms emerge Benefit of existing symptomatic therapies diminishes as disease progresses No disease-modifying therapy available Parkinson’s disease Source: Kal

  11. Slide 11: PD-GBA and neuronopathic Gaucher disease are a continuum of pathology

    Number and severity of GBA1 mutations ➜ Decreasing enzyme activity ➜ Increasing disease severity PD-GBA and neuronopathic GD are a continuum of pathology with the same underlying genetic mechanism “Sporadic” Parkinson’s PD-GBA with less severe phenotype PD-GBA with more severe phenotype Type 1 Gauch

  12. Slide 12: PR001 mechanism of action in PD-GBA

    PR001 mechanism of action in PD-GBA PR001 Treated Parkinson’s Disease WITH GBA1 MUTATION

  13. Slide 13: PR001 CBE mouse model efficacy results

    PR001 CBE mouse model efficacy results Means are presented +/- SEM. *: p<0.05; **: p<0.01; ***: p<0.001. By one-way ANOVA and Fischer’s exact test for glial scarring. For rotarod, nominal p values were calculated by linear regression in the CBE-treated groups, with gender corrected for as a covariat

  14. Slide 14: PR001 genetic mouse model efficacy results

    PR001 genetic mouse model efficacy results PR001 increased GCase enzyme activity (cortex) 4L/PS-NA mice exhibited glycolipid accumulation PR001 suppressed lipid accumulation (cerebellum) 4L/PS-NA mice exhibited motor behavior dysfunction PR001 improved motor function in a beam walk test Each bar rep

  15. Slide 15: PR001 safety and GCase expression in NHPs

    PR001 safety and GCase expression in NHPs NHP biodistribution with ICM delivery No PR001-related safety events or adverse findings were observed in three NHP studies Highest dose tested in NHPs provides: 9x safety margin to PD-GBA starting dose 5x safety margin to nGD starting dose Safety Broad dist

  16. Slide 16: PR001 PD-GBA Phase 1/2 trial

    PR001 PD-GBA Phase 1/2 trial Randomized, double-blind, sham procedure-controlled PR001 Low Dose vs. Placebo (N=8, 6:2) PR001 High Dose vs. Placebo (N=8, 6:2) Single or biallelic GBA1 mutations Moderate to severe Parkinson’s disease Stable background PD medication Safety and tolerability Key biomarke

  17. Slide 17: Goal of PR001 treatment is to restore GCase activity in PD-GBA patients

    Goal of PR001 treatment is to deliver the GBA1 gene to restore GCase activity in PD-GBA patients GCase Enzyme Activity (Illustrative) Human genetics suggest increasing GCase activity by 20-30% of healthy levels expected to be clinically meaningful Similarly, mouse data suggests 20-30% increase in GC

  18. Slide 18: PR001 Type 2 Gaucher disease Phase 1/2 trial

    ICM: intra-cisterna magna; QoL: quality of life; SoC: standard of care; PEG: percutaneous endoscopic gastrostomy PR001 (Open label, N=15) Infants 0-24 months old Biallelic GBA1 mutations Neurological signs & symptoms consistent with Type 2 Gaucher disease Stable SoC background medications Safety and

  19. Slide 19: PR001 Type 3 Gaucher disease Phase 1/2 trial

    ICM: intra-cisterna magna; QoL: quality of life; ICM: intra-cisterna magna; QoL: quality of life; ERT: enzyme replacement therapy PR001 (Open label, N=21) Safety and tolerability Key biomarkers: GCase, GluCer, GluSph (CSF and blood) Efficacy: behavior, cognition, gross motor, function, QoL Type 3 Ga

  20. Slide 20: PR001 market opportunity

    PR001 market opportunity Neuronopathic GD Source: Lancet Neurol 2018; 17: 939–53, N Engl J Med. 2009 Oct 22; 361(17): 1651–1661, Lancet Neurol. 2012 Nov; 11(11): 986–998, Parkinson’s Prevalence Project, Hematology. 2017 Mar;22(2):65-73; J Hum Genet. 2017 Aug;62(8):763-768; J Pediatr. 2015 Jan;166(1)

  21. Slide 21: PR006 overview

    PR006 overview Lead Indications Progress and Status PR006 AAV9 viral vector delivering the GRN gene, which encodes progranulin Route of Administration Single intra-cisterna magna (ICM) injection Frontotemporal dementia with GRN mutation (FTD-GRN) Rapidly progressive dementia impacting behavior and l

  22. Slide 22: FTD-GRN is caused by progranulin deficiency

    Frontotemporal dementia with GRN mutation is caused by progranulin deficiency Healthy Brain NEURON SURVIVAL FTD-GRN NEURONAL CELL DEATH NORMAL PROGRANULIN REDUCED PROGRANULIN LYSOSOME LYSOSOMAL DYSFUNCTION NEURON NEURON AGGREGATES PROGRANULIN DEGRADED PRODUCTS FTD pathology includes neurodegeneratio

  23. Slide 23: Number of GRN mutations and spectrum of disease

    Frontotemporal Dementia (Adult onset) 1 mutation (Heterozygous) Number of GRN mutations ➜ Decreasing progranulin ➜ Increasing disease severity Number of GRN mutations causes varying degrees of progranulin deficiency resulting in spectrum of disease Healthy Individuals 0 mutations Neuronal Ceroid Lip

  24. Slide 24: PR006 efficacy in human FTD-GRN neuronal cultures

    PR006 efficacy in human FTD-GRN neuronal cultures iPSC-derived neurons from FTD-GRN mutation carriers Progranulin expression Cathepsin D maturation Insoluble TDP-43 levels iPSC-derived neurons from humans with FTD-GRN mutations secreted less progranulin than neurons derived from healthy controls PR0

  25. Slide 25: PR006 efficacy in Grn knockout mice

    PR006 efficacy in Grn knockout mice Neuroinflammation Substrate reduction Progranulin expression Lipofuscin accumulation (hippocampus) Neuroinflammation (Tnf mRNA) (cerebral cortex) Progranulin mRNA (cerebral cortex) PR006 dose-dependently reduced accumulation of lipofuscin, an indicator of lysosoma

  26. Slide 26: PR006 safety and progranulin expression in NHPs

    PR006 safety and progranulin expression in NHPs PR006 administration resulted in widespread transduction in the CNS and periphery, and elevated progranulin protein levels in the CSF No adverse PR006-related findings (clinical and histopathological endpoints) Third-party pathologist classified "extre

  27. Slide 27: PR006 FTD-GRN Phase 1/2 trial

    ICM: intra-cisterna magna; NfL: neurofilament light chain; CDR plus NACC FTLD: Clinical Dementia Rating plus National Alzheimer’s Coordinating Center Frontal Temporal Lobar Dementia; QoL: quality of life PR006 (Open label, N=15) 30-80 years old Single pathogenic GRN mutation Symptomatic disease stag

  28. Slide 28: PR006 market opportunity

    Progressive and devastating early-onset form of dementia Leads to death within 3-10 years No therapies approved for FTD No therapies have shown disease modification PR006 market opportunity Disease Overview Treatment & Unmet Need Market Size FTD-GRN FTD prevalence ~50,000 in US; ~800-110,000 in EU 5

  29. Slide 29: CMC strategy and capabilities

    CMC strategy and capabilities Established internal process development capabilities; working with CDMOs to supply clinical trials with drug product Robust adherent HEK293 process to maximize speed to the clinic Partnership with established CDMO Phase 3 and Commercial Material Phase 1/2 Material Bacu

  30. Slide 30: Prevail Therapeutics summary

    Prevail Therapeutics summary Developing potentially disease-modifying gene therapies for neurodegenerative disorders PR001 Phase 1/2 trial for PD-GBA ongoing and enrolling patients PR001 Phase 1/2 trial for nGD on track to initiate in 2020 PR006 Phase 1/2 trial for FTD-GRN on track to initiate in 20

Prevail Therapeutics — Investor Presentation (March 2020) on 6ix